Latest Biotech News

Pacific Biosciences unveiled a plan to let select customers reuse its most expensive SMRT cell consumables and launched a new sequencing chemistry, Sprq‑Nx, to raise throughput and add...

The FDA extended its review of Denali Therapeutics’ biologics license application for tividenofusp (tivi), an enzyme replacement therapy for Hunter syndrome, moving the PDUFA date three months to...

Benchling is integrating NVIDIA BioNeMo models and NIM microservices into its Benchling AI platform to let scientists run protein structure prediction (OpenFold2) and other biomolecular AI tools...

Krystal Biotech became the second company to secure the FDA’s platform technology designation for a genetically modified, non‑replicating herpes simplex virus type platform, which can streamline...

Bio‑Techne and Oxford Nanopore extended and broadened their partnership through 2032 to develop a portfolio of targeted nanopore sequencing kits for screening and diagnosing heritable genetic...

SPT Labtech and 10x Genomics announced a strategic partnership to automate single‑cell workflows by integrating SPT’s Firefly liquid‑handling system with 10x’s Chromium single‑cell chemistry and...

Johnson & Johnson announced plans to spin out its orthopedics business into a standalone company that will retain the DePuy Synthes name, aiming to create a focused competitor to Stryker and...

BioCryst announced a cash-and-stock acquisition of Astria Therapeutics that values the buyered company at roughly $700 million and centers on Astria’s long-acting injectable navenibart for...

Kailera Therapeutics closed a $600 million Series B led by Bain Capital to fund global trials of its obesity injectable, following late‑stage success in China. The financing ranks among the...

Benchling announced integration of NVIDIA’s BioNeMo models and NIM microservices into its Benchling AI platform, enabling users to run Nvidia OpenFold2 predictions and other biomolecular models...

Lila Sciences expanded its Series A with a new $115 million tranche that included investment from Nvidia’s venture arm, taking the round to about $350 million total. The Flagship Pioneering‑backed...

The FDA extended its review of Denali Therapeutics’ application for tividenofusp (tivi), an enzyme replacement therapy for Hunter syndrome, issuing a three‑month delay that moves the PDUFA date to...

AstraZeneca reportedly struck a U.S. drug‑pricing agreement following the administration’s MFN/onshoring talks, while separate reporting flagged a Novo Nordisk manufacturing site in Bloomington,...

Bristol Myers Squibb agreed to acquire Orbital Therapeutics for roughly $1.5 billion to secure an in vivo cell therapy platform targeting autoimmune diseases. Orbital’s approach aims to deliver...

Tvardi Therapeutics’ Phase II study of its oral STAT3 inhibitor for idiopathic pulmonary fibrosis (IPF) failed to meet safety and efficacy endpoints and suffered high dropout rates, prompting an...

Astellas reported that zolbetuximab (Vyloy), a CLDN18.2‑targeting monoclonal antibody, did not meet the primary overall survival endpoint in the Gleam Phase II trial for advanced pancreatic...

Researchers unveiled MetaGraph, a search engine designed to index and query petabases of biological sequencing data, enabling fast retrieval of DNA, RNA and protein patterns from massive public...

Novo Nordisk agreed to acquire Akero Therapeutics in a deal valued at up to $5.2 billion to secure efruxifermin, a Phase III FGF21 analogue for metabolic dysfunction‑associated steatohepatitis...

Bristol Myers Squibb agreed to acquire Orbital Therapeutics for about $1.5 billion to secure an in vivo cell therapy platform targeting autoimmune disease. BMS said the purchase brings an in‑house...

Kailera Therapeutics raised $600 million in a Series B led by a Bain‑led syndicate to advance its lead obesity program into Phase 3 by year‑end. The financing—one of the largest private biotech...